Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia
Sponsor: GlaxoSmithKline
A PHASE3 clinical study on Prostatic Hyperplasia, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain, Aalborg, Denmark, Aalen, Germany, Aarhus N, Denmark, Abrantes, Portugal, Acireale (CT), Italy, Agny, France, Aichach, Germany, Alava, Spain, Albuquerque, United States and 412 more location s